Clinical trials: Blood Cancers, open to volunteers
Malignancy, Hematologic, Neoplasms, Hematologic
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Background: Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RAS genes. These mutations can cause the cancer cells to create substances called neoepitopes.
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer
- Trial name
- NCT06904066
- Testing
- aldesleukin, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Blood Stream Infections, Adult Cancer Patients
Antimicrobial Resistance and Genomic Profiling of Bacterial Isolates
Sepsis and bloodstream infection (BSI) are among the most serious complications in patients with cancer, in whom disease- and treatment-related immunosuppression markedly increases susceptibility to infection.
- Trial name
- NCT07884942
- Testing
- Identification of bacterial isolates causing blood stream infection and determination of their antibiotic sensitivity, Molecular characterization of bacterial isolates
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- Sohag University
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers.
- Trial name
- NCT05436418
- Testing
- Melphalan, Sirolimus, Total Body Irradiation (TBI)
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancy, Leukemia
Better Leukemia Diagnostics Through AI (BELUGA)
To the best of our knowledge, BELUGA will be the first prospective trial investigating the usefulness of deep learning-based hematologic diagnostic algorithms.
- Conditions
- Hematologic Malignancy, Leukemia, Minimal Residual Disease, Lymphoma
- Trial name
- BELUGA (NCT04466059)
- Testing
- Automated AI-Guided Diagnosis of Hematological Malignancies
- Where
- Germany
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Munich Leukemia Laboratory
Blood Cancers, Blood Cancer
Rutgers University Study of the Genetics of Blood Cancers
The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct…
- Conditions
- Blood Cancers, Blood Cancer, Leukemia, Lymphoma
- Trial name
- NCT07714044
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Leucogen, Ribociclib
the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer
This study is a multicenter, single-arm, open-label Phase II exploratory clinical trial designed to evaluate whether prophylactic use of leucogen can reduce the incidence of Grade 3 or higher neutropenia in early-stage HR+/HER2…
- Conditions
- Leucogen, Ribociclib, Neutropenia (Low White Blood Cell Count), Breast Cancer
- Trial name
- NCT07380646
- Testing
- Treat Regimen
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Intracranial Venous Blood, Brain Cancers
A Study to Evaluate the Safety and Efficacy of Intracranial Venous Blood Sampling for Liquid Biopsy in the Diagnosis of Brain Cancers
To learn if drawing blood directly from veins inside the brain is safe and can effectively provide the same kind of detailed information about high-grade glioma as traditional surgical biopsy.
- Conditions
- Intracranial Venous Blood, Brain Cancers, Liquid Biopsy, Evaluate the Safety
- Trial name
- NCT07467109
- Testing
- blood sampling
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma in Relapse, Myeloma Multiple
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
The goal of this clinical trial is to evaluate the safety, tolerability, and recommended Phase 2 Dose (RP2D) of KLN-1010 in patients with relapsed or refractory multiple myeloma.
- Conditions
- Multiple Myeloma in Relapse, Myeloma Multiple, Multiple Myeloma Progression, Neoplasms by Histologic Type
- Trial name
- inMMyCAR (NCT07075185)
- Testing
- KLN-1010
- Where
- 11 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Kelonia Therapeutics, Inc.
Multiple Myeloma, Triple Negative Breast Cancer
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
This study is comprised of a main study, an observational study, and optional survey studies. The main study is being done to see whether using Duffy null specific treatment dosing guidelines can reduce or delay dose…
- Conditions
- Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
- Trial name
- NCT07341867
- Testing
- Dexamethasone, Bortezomib, LENALIDOMIDE
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Andrew Hantel, MD
Hematologic Malignancies, Lymphoma
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
The purpose of this study is to evaluate whether a novel decision support tool called PRIME (Preference Reporting to Improve Management and Experience), which combines values-elicitation with tailored feedback to patients and…
- Conditions
- Hematologic Malignancies, Lymphoma, Multiple Myeloma, Leukemia
- Trial name
- DISCOVERY (NCT06296368)
- Testing
- Preference Reporting to Improve Management and Experience (PRIME)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Blood Cancer
Allogeneic T Cells Expressing T Cell Receptor-KDEL and the Chimeric Antigen Receptor CAT19 for the Treatment of Advanced CD19+ Malignancies
KCAT19 is a single-centre, non-randomised, open-label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in adults (age 16-65 years) with high risk, relapsed/refractory (r/r) B cell…
- Trial name
- KCAT19 (NCT05391490)
- Testing
- KCAT19 T cells
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- University College, London
Blood Cancer, Leukemia
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
The purpose of this research study is to enhance inclusion and diversity in clinical trial enrollment by training participants to perform and provide feedback through a community-based protocol review process, called DIVERSE.
- Trial name
- DIVERSE (NCT06469307)
- Testing
- DIVERSE Review Process
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer, Surgery
Electric Cardiometry-Guided Standard Versus Restricted Fluid Therapy In Robotic Prostaectomy
Fluid therapy during surgery is an important factor that is related to long term mortality and morbidity and it's directly related to tissue perfusion as well.
- Conditions
- Prostate Cancer, Surgery, Fluid Overload, Lactate Blood Increase
- Trial name
- NCT07626151
- Testing
- Liberal Fluid Therapy, Restricted Fluid Therapy
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Nazmy Edward Seif
Neoplasms, Blood Cancer
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
Cancer-related fatigue affects at least 30-90% of patients with cancer, depending on the type of cancer and their treatment(s) (e.g., chemotherapy, radiation).
- Conditions
- Neoplasms, Blood Cancer, Fatigue, Diet Habit
- Trial name
- NCT06482515
- Testing
- Time-restricted eating, Nutrition counseling
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- University of Maryland, Baltimore
Prostate Cancer (Adenocarcinoma), Blood Loss, Postoperative
EFFICACY OF INTRAOPERATIVE ARISTA POLYSACCHARIDE APPLICATION ON THE POSTOPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING RARP FOR THE TREATMENT OF PROSTATE CANCER
We perform a multicenter randomized controlled prospective study with superiority trial design, in which the polysaccharide ARISTA™ AH hemostat agent is applied to the neurovascular bundle areas after prostate removal, during…
- Conditions
- Prostate Cancer (Adenocarcinoma), Blood Loss, Postoperative, Erectile Function
- Trial name
- ARISTA (NCT06822036)
- Testing
- Arm A - Application of 5g of ARISTA™ AH
- Where
- 3 sites in Germany
- Volunteers
- 362 people
- Sponsor
- St. Antonius Hospital Gronau
Triple Negative Breast Cancer, Blood and Image Guided
Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial
To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.
- Conditions
- Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2
- Trial name
- NCT07610525
- Testing
- Paclitaxel + Carboplatin, Pembrolizumab
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Blood Cancer, Lymphoma
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
Research has shown that music-based activities may help improve brain functions, such as attention, memory, and executive function.
- Conditions
- Blood Cancer, Lymphoma, Leukemia, Myeloma
- Trial name
- NCT07052916
- Testing
- Music Therapy/MT, Therapist-Attention Music Education/TAME Control
- Where
- 7 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Kidney Disease, Proteinuria
A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) Guidelines
The goal of this study is to establish whether use of a digital intervention can improve adherence and alignment with the Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) 2024 Guidelines.
- Conditions
- Chronic Kidney Disease, Proteinuria, Blood Pressure Control, Congenital Anomalies of the Kidneys and Urinary Tract
- Trial name
- NCT07561957
- Testing
- Use of an electronic digital Application
- Where
- 2 sites in Ireland
- Volunteers
- 80 people
- Sponsor
- St. James's Hospital, Ireland
Hematologic Malignancy, Blood Cancer
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular…
- Conditions
- Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia
- Trial name
- PEACE (NCT05646576)
- Testing
- Palliative Care, Usual Care
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Massachusetts General Hospital
Fungal Infection, Haematological Malignancy
Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial
This project aims to address invasive fungal infections in patients, by precision dosing of voriconazole based on CYP2C19 genotype testing with Bayesian dose-forecasting dosing software to develop patient-centric and maximally…
- Conditions
- Fungal Infection, Haematological Malignancy, Blood Cancer, Infectious Disease
- Trial name
- PRAGMATIC (NCT06510699)
- Testing
- genotype-directed dosing with dosing software based on therapeutic drug monitoring
- Where
- 7 sites in United States, Australia
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- The University of Queensland